Zepbound® Weight Loss Program in Chandler, Gilbert & Mesa, Arizona

---

Zepbound®: The First FDA-Approved Dual Receptor Weight Loss Injection

Zepbound® represents a genuine breakthrough in the pharmacological treatment of obesity. It is the first and only medication to receive FDA approval for chronic weight management based on dual GIP and GLP-1 receptor agonism—meaning it activates two separate metabolic hormone pathways rather than one.

What Is the GLP-1 Receptor?

GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. GLP-1 receptor activation slows gastric emptying to extend post-meal fullness, suppresses hunger signaling in the hypothalamus to reduce food cravings, and stimulates insulin secretion proportionally to blood sugar levels. These effects are the basis of all GLP-1 medications, including Ozempic® and Wegovy®.

What Is the GIP Receptor — and Why Does It Matter?

GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that works in parallel with GLP-1. GIP receptor activation enhances the insulin response further, improves insulin sensitivity in fat tissue, and amplifies appetite suppression through complementary brain pathways. Critically, GIP activation also appears to buffer the nausea and gastrointestinal side effects that some patients experience with GLP-1-only medications—making Zepbound® better tolerated during titration for many patients.

The SURMOUNT Trial Results

In the landmark SURMOUNT-1 and SURMOUNT-2 clinical trials, patients treated with Zepbound® achieved average weight reductions of 15–22% of total body weight at 72 weeks. At the maximum 15 mg dose, average weight loss approached 22%—the highest outcomes ever recorded for an FDA-approved pharmaceutical weight loss treatment. These results approach outcomes previously associated only with bariatric surgery.

---

How Zepbound® Works: Four Key Mechanisms

Tirzepatide’s dual receptor mechanism produces four synergistic physiological effects that together create a powerful, sustained environment for weight loss:

1. Extended Post-Meal Fullness

Zepbound® slows gastric emptying so food moves from the stomach to the intestine more slowly—keeping you comfortably full for hours after a meal. Most patients find that portion control and meal spacing become natural rather than effortful, removing one of the most common barriers to sustained calorie reduction.

2. Powerful Appetite & Craving Suppression

The combined GLP-1 and GIP receptor activation produces stronger suppression of hunger signaling than either mechanism alone. The result is a dramatic reduction in “food noise”—the persistent mental preoccupation with eating and cravings for calorie-dense foods. Many patients describe this as a fundamental shift in their relationship with food, not simply feeling less hungry.

3. Precise Blood Sugar Regulation

Zepbound® stimulates insulin release in direct proportion to blood sugar elevation while limiting the liver’s excess glucose output. This produces exceptionally stable blood sugar throughout the day—eliminating energy crashes, mood disruptions, and reactive cravings that stem from glycemic instability. Even patients without diabetes benefit from this stabilization through more consistent energy and better sleep quality.

4. Broad Metabolic & Cardiovascular Improvement

Beyond weight, clinical data from the SURMOUNT program documents meaningful reductions in blood pressure, LDL cholesterol, triglycerides, and waist circumference. Cardiovascular risk markers improve significantly—effects that exceed what weight loss alone would predict. Emerging research also documents benefits in sleep apnea severity, non-alcoholic fatty liver disease (NAFLD/NASH), and kidney function.

---

Why Chandler, Gilbert & Mesa Patients Choose New Viva MD for Zepbound®

Zepbound® is the most powerful FDA-approved weight loss medication currently available—and that makes physician oversight more important, not less. Online subscription services can send you a prescription. They cannot provide the medical evaluation, titration management, and ongoing accountability that get you to your best outcome safely.

Board-Certified Physician Oversight

Your care is directed by a licensed MD. Zepbound® requires careful dose titration from 2.5 mg to a target of 5–15 mg weekly. Our physician manages this process based on your individual tolerance and response—not a generic auto-titration schedule. This makes a meaningful difference in both side effect management and ultimate weight loss outcomes.

Comprehensive Pre-Treatment Evaluation

Before prescribing, we review your complete health history, current medications, metabolic labs, thyroid history, and personal and family cancer history. Zepbound® has specific contraindications that require careful medical screening—a step that online platforms routinely shortcut.

Integrated Lifestyle Coaching

Medication is a powerful catalyst, but not a permanent solution on its own. We pair every Zepbound® prescription with nutritional guidance and behavioral coaching designed to build the habits that outlast treatment. When the time comes to taper, you are prepared to maintain your results.

Conveniently Located for East Valley Patients

Our office at 2390 West Ray Road in Chandler is minutes from Gilbert and Mesa. Patients from across the East Valley receive physician-grade care without traveling to Scottsdale or central Phoenix.

Transparent Cost, Insurance & Savings Card Guidance

Zepbound® has broader insurance coverage for weight loss than Mounjaro® or Ozempic®, as it carries a specific FDA weight management indication. Eli Lilly also offers substantial savings card programs for eligible commercially insured patients. We help you navigate every available option during your consultation so there are no surprises.

Long-Term Monitoring & Transition Planning

We schedule regular follow-ups throughout your treatment course—monitoring weight, metabolic markers, and side effects, and adjusting dosing in real time. We also plan ahead for eventual transition off medication, with a clear strategy for maintaining your results independently.

---

Benefits of the New Viva MD Zepbound® Program

When the most advanced FDA-approved weight loss medication is paired with physician supervision and lifestyle coaching, the clinical outcomes are exceptional:

• Highest Documented Weight Loss: SURMOUNT trial data shows average reductions of 15–22% of total body weight—results that approach bariatric surgery outcomes and represent the most powerful pharmaceutical weight loss ever documented.
• FDA-Approved for Weight Management: Unlike Mounjaro® or Ozempic®, Zepbound® carries a specific FDA approval for chronic weight management—improving insurance coverage eligibility and removing the off-label prescription requirement.
• Dual GIP+GLP-1 Mechanism: Stronger appetite suppression, better glycemic stability, and greater fat loss than single-receptor GLP-1 medications—through two synergistic pathways rather than one.
• Improved GI Tolerability: GIP receptor activation appears to buffer nausea and gastrointestinal side effects that some patients experience with GLP-1-only medications, making Zepbound® more tolerable during titration for many.
• Broad Metabolic Benefits: Clinically meaningful improvements in blood pressure, LDL cholesterol, triglycerides, and cardiovascular risk—beyond what weight loss alone predicts.
• Emerging Additional Benefits: Growing evidence documents improvements in sleep apnea severity, NAFLD/NASH, kidney function, and joint health as secondary benefits of sustained tirzepatide treatment.
• Increased Energy & Mobility: Patients report dramatic gains in daily energy, joint comfort, sleep quality, and motivation for physical activity as weight decreases.
• Physician-Monitored Safety: Regular check-ins ensure safe, effective titration and allow early detection of any adverse effects throughout your full treatment course.

---

Is Zepbound® Right for You?

During your consultation, our physician conducts a thorough medical evaluation to confirm candidacy. The following is a general overview of qualification criteria.

Strong Candidates

• BMI of 30 or above
• BMI 27+ with at least one weight-related condition such as hypertension, Type 2 diabetes, dyslipidemia, sleep apnea, or cardiovascular disease
• Patients who have tried GLP-1-only medications (Ozempic® or Wegovy®) and want stronger results or better tolerability
• Patients seeking the FDA-approved weight management indication for insurance coverage purposes
• No known allergy or sensitivity to tirzepatide or GIP/GLP-1 receptor agonist components
• Willingness to engage with lifestyle modifications alongside medication
• Age 18 and older

Not Currently Eligible

• Personal or family history of medullary thyroid carcinoma (MTC)
• Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Current pregnancy or active breastfeeding
• Known hypersensitivity to tirzepatide or any component of the formulation
• Under 18 years of age

Note: This is general guidance only. Final candidacy is determined by physician evaluation. Lab work, thyroid history review, and other diagnostics are completed as part of your assessment.

---

What to Expect at New Viva MD

From your first call to long-term follow-up, every step is designed around your safety and results.

Step 1: Comprehensive Consultation

Your physician reviews your complete health history, current medications, metabolic markers, thyroid and cancer family history, and prior weight loss attempts. A physical exam and body composition analysis is completed. If you have previously used Ozempic® or Mounjaro®, we evaluate your response and determine whether Zepbound®’s FDA-approved indication is a better clinical and coverage fit. All questions are answered with no pressure and no obligation.

Step 2: Personalized Treatment Plan

If Zepbound® is appropriate for you, we build a protocol around your starting dose and titration schedule. Treatment begins at 2.5 mg weekly and increases gradually every four weeks—to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg as tolerated—reaching the lowest effective maintenance dose. The once-weekly subcutaneous injection is self-administered using Zepbound®’s auto-injector pen with an ultra-fine needle. Most patients describe it as near-painless.

Step 3: Ongoing Monitoring & Transition Planning

Scheduled follow-up appointments track weight, lab values, blood pressure, and relevant health markers as your body changes. Side effects are addressed proactively and dosing adjusted in real time. Your physician also develops a long-term transition plan well before you approach your goal weight—so you are fully prepared to maintain results when medication is eventually tapered.

---

Zepbound® vs. Other Weight Loss Medications

Here is how Zepbound® compares to other leading weight loss options. Your physician will help identify the right fit at your consultation.

Feature	Zepbound® (Tirzepatide)	Mounjaro® (Tirzepatide)	Wegovy® (Semaglutide)
FDA Approval	Weight Management (FDA-approved)	Type 2 Diabetes (off-label for weight)	Weight Management (FDA-approved)
Active Ingredient	Tirzepatide	Tirzepatide	Semaglutide
Mechanism	GLP-1 + GIP Dual Receptor Agonist	GLP-1 + GIP Dual Receptor Agonist	GLP-1 Receptor Agonist only
Dosing	Once weekly injection	Once weekly injection	Once weekly injection
Max Dose	15 mg / week	15 mg / week	2.4 mg / week
Typical Weight Loss	15-22% body weight	15-22% body weight	12-17% body weight
Insurance (Weight)	Coverage expanding; on-label indication	Varies; often better for T2D patients	Varies by plan
Best For	Weight management without T2D; max results; insurance coverage	Patients with T2D and weight goals	Single-receptor GLP-1 preference

Note: Medication selection is determined by individual clinical evaluation. All options require a physician prescription. Insurance coverage varies by plan and diagnosis. This table is for general patient education only.

---

Zepbound® vs. Mounjaro®: Same Drug, Different Indication

Zepbound® and Mounjaro® contain the same active ingredient—tirzepatide—at the same doses. The critical difference is their FDA-approved indication:

• Mounjaro®: FDA-approved for Type 2 diabetes management. When prescribed for weight loss in patients without T2D, it is used off-label. Insurance coverage for weight loss is less consistent under this indication.
• Zepbound®: FDA-approved specifically for chronic weight management in adults with a BMI ≥30 (or ≥27 with a qualifying weight-related condition). This on-label status can improve insurance coverage for weight loss and removes the off-label prescription requirement.

For most patients seeking weight loss who do not have a Type 2 diabetes diagnosis, Zepbound® is the more appropriate and often more cost-effective choice. Your physician will evaluate which formulation is right for your situation—including how each interacts with your specific insurance plan.

---

Serving Chandler, Gilbert & Mesa, AZ

Our office is located in Chandler to serve patients across the East Valley with minimal commute time.

Chandler (Main Office)

2390 West Ray Road #1, Chandler, AZ 85224  |  (480) 331-4316

Physician-led practice dedicated to medical weight loss, aesthetics, and wellness. Easy freeway access from the Loop 101 and Loop 202.

Gilbert Patients

Patients from Gilbert, San Tan Valley, and Queen Creek visit our Chandler office—minutes east via Chandler Boulevard or Ray Road. Approx. 10–15 minutes from central Gilbert. No need to travel to Scottsdale or Phoenix for top-tier physician-supervised care.

Mesa Patients

South and East Mesa patients find our Chandler location far more accessible than clinics in central Phoenix or Scottsdale. Same physician-supervised standard of care, significantly closer to home. Approx. 15–20 minutes from south Mesa.

---

Frequently Asked Questions